Literature DB >> 16419419

Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature.

Annabelle A Okada1.   

Abstract

Corticosteroids are used as first-line treatment for many ocular inflammatory conditions. The risk of adverse effects, however, necessitates conversion to steroid-sparing immunomodulatory therapy (IMT) for disease that is recurrent, chronic, or poorly responsive to treatment. Combination drug treatments with multiple agent 'recipes' are also considered. Immunomodulatory agents include the broad categories of antimetabolites (azathioprine, methotrexate, mycophenolate mofetil), alkylating agents (cyclophosphamide, chlorambucil), T-cell inhibitors (cyclosporine, tacrolimus), and cytokines (interferon alfa). This article reviews and summarizes the evidence for IMT agent use in the treatment of various forms of ocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16419419     DOI: 10.1080/09273940590951034

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  20 in total

Review 1.  Biologic therapy for refractory scleritis: a new treatment perspective.

Authors:  Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani
Journal:  Int Ophthalmol       Date:  2015-08-29       Impact factor: 2.031

2.  Mycophenolate mofetil monotherapy in the management of paediatric uveitis.

Authors:  P Y Chang; G P Giuliari; M Shaikh; P Thakuria; D Makhoul; C S Foster
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

Review 3.  Non-infectious pediatric uveitis: an update on immunomodulatory management.

Authors:  Srilakshmi M Sharma; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 4.  Uveitis: advances in understanding of pathogenesis and treatment.

Authors:  Russell W Read
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

5.  A 36-year-old man with a red eye.

Authors:  Drew Chronister; Evan Waxman
Journal:  Digit J Ophthalmol       Date:  2008-04-13

Review 6.  [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].

Authors:  N Stübiger; S Winterhalter; U Pleyer; D Doycheva; M Zierhut; C Deuter
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

Review 7.  Emerging drugs for uveitis.

Authors:  Theresa Larson; Robert B Nussenblatt; H Nida Sen
Journal:  Expert Opin Emerg Drugs       Date:  2011-01-06       Impact factor: 4.191

8.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

9.  Methotrexate for ocular inflammatory diseases.

Authors:  Sapna Gangaputra; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; John H Kempen
Journal:  Ophthalmology       Date:  2009-09-12       Impact factor: 12.079

10.  Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.

Authors:  Jungyeon Hwang; Kathleen Rodgers; James C Oliver; Thomas Schluep
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.